Investor Series: Opportunities in the Digital Therapeutics Market (Focus on Need for Digital Therapeutics, Market Landscape of Innovators, Analysis of Product Offerings and Affiliated Value Propositions, Insights from Historical Funding Activity, Company Health Indexing, Financial Analysis of Key Public Ventures, Market Forecast and Opportunity Analysis, Insights from Publicly Disclosed Investor Exits and Key Acquisition Targets)

  • Lowest Price Guaranteed From USD 1,899

  • Published
    January 2023

  • Slides
    179

  • View Count
    184

Example Insights

Investor-Series-Digital-Therapeutics-Market-Context-thumb Investor-Series-Digital-Therapeutics-Market-Contemporary-Sentiments-thumb Investor-Series-Digital-Therapeutics-Market-Digital-Therapeutics-thumb Investor-Series-Digital-Therapeutics-Market-Innovators-Landscape-thumb Investor-Series-Digital-Therapeutics-Market-Company-Health-Indexing-thumb Investor-Series-Digital-Therapeutics-Market-Value-Proposition-Analysis-thumb Investor-Series-Digital-Therapeutics-Market-Company-Competitiveness-Analysis-thumb
Investor-Series-Digital-Therapeutics-Market-Analysis-of-Investments-thumb Investor-Series-Digital-Therapeutics-Market-Capital-Investments-thumb Investor-Series-Digital-Therapeutics-Market-capital-Investors-thumb Investor-Series-Digital-Therapeutics-Market-Funding-and-Investment-Activity-thumb Investor-Series-Digital-Therapeutics-Market-Financial-Analysis-thumb Investor-Series-Digital-Therapeutics-Market-Future-Capability-thumb Investor-Series-Digital-Therapeutics-Market-Stock-Performance-thumb
Investor-Series-Digital-Therapeutics-Market-Technical-Analysis-thumb Investor-Series-Digital-Therapeutics-Market-Akili-Interactive-thumb Investor-Series-Digital-Therapeutics-Market-Business-Risk-Assessment-thumb Investor-Series-Digital-Therapeutics-Market-Type-of-Solution-thumb Investor-Series-Digital-Therapeutics-Market-Estimated Return-thumb Investor-Series-Digital-Therapeutics-Market-Key-Acquisition-Targets-thumb  

Overview

Digital therapeutics are clinically validated solutions that are delivered as applications, software and online programs, demonstrating the capability to facilitate positive outcomes when employed in the management of clinical conditions. These therapeutics are designed to engage patients in personalized treatment or disease prevention programs, through mediating behavioral or psychological modifications. The primary benefits of digital therapeutics include reduction of treatment related costs, generation and maintenance of personalized health data, reduction in stress amongst healthcare professionals, and increase in the adherence to prescribed treatment regimens. In addition, these digital health solutions provide motivational support and inculcate healthy lifestyle changes in the target patient population. Currently, a wide variety of digital health applications and intuitive software are available for the aforementioned purposes. In fact, the COVID-19 pandemic has created a significant demand for remote healthcare solutions. Amidst other alternatives, digital therapeutics have emerged as a promising option since these can be employed as preventive or curative digital solutions for managing diverse target indications. A recent survey highlighted that the percentage of patients adopting digital therapeutics in the US rose from 4.7% to 18%, post the pandemic outbreak, resulting in an increased prescription rate of such therapeutics. Presently, there are more than 40 USFDA approved digital therapeutic solutions available in the market, including apps, software and devices, for the management of numerous therapeutic areas, such as mental health disorders, substance use disorders and reproductive health. It is worth noting that reSET, developed by Pear Therapeutics, was the first prescription digital therapeutics that received the USFDA approval in 2017. The application can be used as a method of opioid replacement therapy, increasing a patient's abstinence from substances of abuse during the treatment and enhancing the outpatient treatment program retention.

Owing to the increased adoption rate of digital solutions and rise in the demand for remote healthcare services, the companies involved in the digital therapeutics domain have witnessed a surge in the investment activity, with capital investments worth more than USD 9 billion. According to the recent trends, various digital therapeutic companies are engaged in providing personalized solutions, along with remote access to medical care facilities, including a health coach. Further, taking into consideration both the historical and contemporary scenarios, we believe that the digital therapeutics market presents lucrative investment opportunities for both short and long-term investors.

Scope of the Report

The Investor Series: Opportunities in the Digital Therapeutics Market (Focus on Need for Digital Therapeutics, Market Landscape of Innovators, Analysis of Product Offerings and Affiliated Value Propositions, Insights from Historical Funding Activity, Company Health Indexing, Financial Analysis of Key Public Ventures, Market Forecast and Opportunity Analysis, Insights from Publicly Disclosed Investor Exits and Key Acquisition Targets) report provides detailed information on the digital therapeutics market, covering the core and peripheral digital therapeutics solutions. It offers a technical and financial perspective on how the opportunity in this domain is likely to evolve, in terms of future business success, over the coming decade. The information in this report has been presented across multiple deliverables, featuring MS Excel sheets (some of which include interactive elements) and an MS PowerPoint deck, which summarizes the key takeaways from the project, and insights drawn from the curated data. The report features the following details:

  • A qualitative and quantitative (wherever information was available) perspective on the current need for digital therapeutics, highlighting some of the key applications of such offerings. Further, it highlights various challenges faced during stages of drug discovery, and the opinions of representatives from key stakeholder companies involved in this domain.
  • A detailed analysis of digital therapeutics focused companies that were established post 2005, featuring inputs on observed trends related to basic input parameters, such as year of establishment, location of headquarters, company size, and type of venture. 
  • A quantitative perspective on the relative health (based on basic company details, product details, financing activity, and estimated revenues and profits) of the different innovator companies that have been described in detail in this report. This analysis is based on a proprietary scoring criterion, informed via secondary research. 
  • An assessment of the various solutions, offered by the companies mentioned above, featuring analysis based on number and types of products, and an informed perspective on the value of the offerings based on multiple relevant aspects, namely outreach-related value offered, developer-related value, value to patients and product-related value.  
  • A company competitiveness analysis, which offers a quantitative basis for comparing the strengths / contributions of various industry stakeholders that are involved in providing digital therapeutic solutions, captured in this report. It is worth mentioning that this analysis is based on the insights generated from the abovementioned relative health indexing and value proposition analyses.
  • A detailed analysis of the funding and investment activity that has taken place in this domain, since 2011. It also includes financing category-wise trends, describing the relative maturity (in terms of number of funding instances and total capital raised) of the innovator companies discussed in the report. Further, it features a list of the leading investors in digital therapeutics, based on their participation in financing activity in this industry segment.  
  • An elaborate review of the overall digital therapeutics market from a financial perspective, including detailed fundamental (insights from the balance sheet, and key financial ratios) and technical analyses (insights from historical and recent stock price variations, and analysis using popular stock performance indicators) of financial data of the publicly listed companies within the market landscape dataset. 
  • A business risk analysis, based on some of the major categories of risk that are usually discussed in the industry, namely operations-related risks, overall business-related risks, financial risks, product / technology associated risks, and social, economic, environmental and political risks. 
  • Case studies of instances where investors have exited various digital therapeutics related ventures, offering insights on return on investments made (based on availability of data). Leveraging the abovementioned details, the report offers an informed opinion on the future outlook for investors in the digital therapeutics market. 
  • A key acquisition targets analysis, based on the insights generated during the course of this study, highlighting some of the promising early-to-mid stage business ventures around which there is likely to be interest for future acquisitions / mergers.

One of the key objectives of the report was to identify the primary growth drivers and estimate the future growth opportunity associated within the digital therapeutics market, over the coming decades. We have provided informed estimates on the likely evolution of the market, during the period 2023-2035, based on various parameters, such as historical sales, target patient population, likely adoption rates and expected pricing. Our year wise projections of the current and forecasted opportunity within the digital therapeutics market have been further segmented across type of solution (standalone software application, combination offerings of software application + device, combination offerings of software application + AI support , combination offerings of software application + personal coach, combination offerings of software application + device + AI support , combination offerings of software application + device + personal coach  and others), type of therapy (curative solutions and preventive solutions), therapeutic area (cardiovascular disorders, chronic pain, mental health problems, metabolic disorders, neurological disorders, respiratory disorders, sleep disorders, substance use disorders and others), and geographical regions (North America, Europe and Asia-Pacific and Rest of the World). In order to account for future uncertainties in the market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter Outlines

EXCEL DELIVERABLE

Spreadsheet I includes details on the companies captured in the report, along with their respective products. It also features proprietary company health indexing analysis, value proposition analysis, insights from a detailed company competitiveness analysis and a list of industry stakeholders that were deemed to be likely targets for mergers / acquisitions, in the near future. The deliverable includes a summary dashboard, featuring interactive graphical representations of key insights generated from the data collated. 

Spreadsheet II features a summary dashboard, including interactive graphical representations of some of the key insights generated related to the capital investments made in digital therapeutics domain (since 2011)

Spreadsheet III is a collection of multiple MS Excel sheets that provide summaries of insights generated from a detailed fundamental and technical financial analysis, of publicly listed ventures in the innovator companies’ dataset. 

Spreadsheet IV offers our independent perspective on the various types of risks (namely operations-related risks, business-related risks, financial / asset-related risks, product / technology risks, and other risks) that the publicly listed ventures are presently exposed to; it includes a summary heat map representation that provides a pictorial perspective of the diversity and level of risks (as per our opinion), as well. 

Spreadsheet V is a summary MS Excel dashboard, offering detailed graphical representations of the contemporary and future opportunity associated with the digital therapeutics domain.

Spreadsheet VI includes publicly available information on the investments made by selected investors in companies that are now publicly listed. Based on the data, we have offered a perspective on likely return on investments received by the mentioned investors.

POWERPOINT DELIVERABLE

Chapter 1 provides a brief summary of the content presented in the report, beginning with the need for digital therapeutics. It goes on to discuss some of the key benefits of these solutions and their advantages over the conventional therapies. Finally, the chapter provides an overview of the current scenario, offering a perspective on how, in light of recent funding activity, the market is likely to evolve over the coming years. 

Chapter 2 and 3 feature brief (pictorial) summaries of the key objectives and approach used for data collection and analysis, in this study. 

Chapter 4 features an executive summary of the key insights generated from the data and analytical outputs presented in the report. 

Section I: Need for Digital Therapeutics and Innovators Landscape
Chapter 5 describes the current need for digital therapeutics, highlighting the key facts about the origin and development of digital therapeutics. It features information on the current areas of innovation, along with opinions of experts, describing various benefits of these therapies, and anticipated future challenges. It includes information on some of the key players that are engaged in this domain. The views presented in this chapter are backed by inputs from representatives from key stakeholder companies in this domain (as stated in publicly available articles and interview transcripts).

Chapter 6 focuses on some of the innovators (companies established on or after 2005) and features detailed analysis of the companies. It highlights important company related details, such as year of establishment, headquarters, company size, and type of venture. 

Chapter 7 includes information on the various products and affiliated services offered by the companies captured in the report (listed in Chapter 6). It also features analysis based on number and types of products. Based on the insights and details presented in Chapter 6, we have developed a quantitative perspective on the relative health (based on basic company details, product details and financing activity) of the different innovator companies. 
Chapter 8 offers an informed perspective on the apparent value proposition of the companies captured in the report (listed in Chapter 6). Based on multiple relevant inputs (as inferred from publicly disclosed value statements), namely outreach-related value offered, developer-related value, value to patients and product-related value, we developed an empirical framework to quantify the value proposition of a business. 

Chapter 9 features a detailed company competitiveness analysis, offering a quantitative basis for comparing the developer of digital therapeutics captured in this report. It is worth mentioning that the analysis described in this section is based on a proprietary scoring criterion, which was informed via our company health indexing. 

Section II Analysis of Investments
Chapter 10 offers insights from a detailed analysis of the funding and investment activity in this domain, since 2011. It includes financing category-wise trends, describing the relative maturity (in terms of number of funding instances and total capital raised) of the innovator companies discussed in the report. 

Section III Financial Analysis and Assessment of Business Risks
Chapter 11 is modelled in the likeness of an equity research report. It features a review of the overall digital therapeutics market from a financial perspective and includes detailed fundamental (insights from the balance sheet, and key financial ratios) and technical analyses (insights from historical and recent stock price variations, and analysis using popular stock performance indicators) of financial data of nine of the publicly listed companies within the innovator landscape dataset. 

Chapter 12 includes detailed profiles of the public ventures engaged in the development of digital therapeutics. Each profile features a brief overview of the company, its insight from balance sheet (if available), details on its management team, a section on recent developments and key financial details (including company investment highlights, company fundamental and company technical analysis)

Chapter 13 includes a business risk analysis, offering insights encompassing several known categories of risk; these include operations-related risks, business-related risks, product / technology risks, financial / asset-related risks, and other risks.

Section IV Market Forecast and Opportunity Analysis
Chapter 14 features an insightful market forecast analysis, highlighting the estimated current and future size of the overall digital therapeutics market, till the year 2035. The opportunity has been segregated on the basis of type of solution (standalone software application, combination offerings of software application + device, combination offerings of  software application + AI support , combination offerings of software application + personal coach, combination offerings of software application + device + AI support , combination offerings of software application + device + personal coach  and others), type of therapy (curative solutions and preventive solutions), therapeutic area (cardiovascular disorders, chronic pain, mental health problems, metabolic disorders, neurological disorders, respiratory disorders, sleep disorders, substance use disorders and others) and geographical regions (North America, Europe, Asia-Pacific and Rest of the World.

Section V Analysis of Returns on Investment and Key Acquisition Targets
Chapter 15 includes case studies of instances where investors have exited various digital therapeutics-related ventures, offering insights on return on investments made (based on availability of data). The abovementioned estimates / details, offer a perspective on how past investments have paid off for investors as companies gradually went public, over time. 

Chapter 16 offers insights from a proprietary analysis that leverages inputs from the startup health indexing and value proposition analysis (described in Section I), to offer qualitative recommendations on companies that are likely to be perceived as key acquisition targets. 

Chapter 17 provides a pictorial summary of the overall project.

Chapter 18 is a set of appendices.

Table Of Contents

EXCEL DELIVERABLE
1. INNOVATORS AND PRODUCTS DATAS
ET 
1.1. Analysis Notes
1.2. Innovator Landscape 
1.3. Product Landscape 
1.4. Value Proposition
1.5. Key Acquisition Targets
1.6. AI – AVII Appendices

2. FUNDING AND INVESTMENT ANALYSIS
2.1. Analysis Notes
2.2. Summary Dashboard
2.3. Capital Investments in Digital Therapeutics
2.4 AI – AIV Appendices

3. FUNDAMENTAL AND TECHNICAL FINANCIAL ANALYSIS
The information presented in this analysis is spread across separate MS Excel sheets, which provide information on key financial parameters and competitive insights based on historical and prevalent trends.

4. BUSINESS RISK ANALYSIS
4.1. Analysis Notes
4.2. Business Risk Data
4.3. AI – AVII Appendices

5. MARKET FORECAST AND OPPORTUNITY ANALYSIS 
5.1. Analysis Notes
5.2. Market Forecast and Opportunity Analysis: Summary
5.3. Market Forecast and Opportunity Analysis: Base Scenario
5.4. Market Forecast and Opportunity Analysis: Conservative Scenario
5.5. Market Forecast and Opportunity Analysis: Optimistic Scenario 

6. RETURN ON INVESTMENT 
6.1. Analysis Notes
6.2. Estimated RoI for Investors in Company A
6.3. Estimated RoI for Investors in Company B
6.4. Estimated RoI for Investors in Company C

POWERPOINT DELIVERABLE

1. CONTEXT 

2. PROJECT APPROACH

3. PROJECT OBJECTIVES

4. EXECUTIVE SUMMARY

Section I: Need for Digital Therapeutics and Innovators Landscape
5. THE DIGITAL THERAPEUTICS MARKET

5.1. Overview
5.2. Historical Milestones
5.3. Key Types of Solutions
5.4. Key Strategic Initiatives
5.5. Key Marketed Products and Challenges associated with Digital Therapeutics

6. DIGITAL THERAPEUTICS: INNOVATOR LANDSCAPE
6.1. Methodology
6.2. Innovators in the Digital Therapeutics Market
6.3. Analysis of Competitive Landscape
6.4. Concluding Remarks 

7. DIGITAL THERAPEUTICS: PRODUCT LANDSCAPE AND COMPANY HEALTH INDEXING
7.1. List of Digital Therapeutics
7.2. Analysis of Product Landscape
7.3. Health Indexing Methodology
7.4. Company Health Indexing
7.5. Concluding Remarks

8. VALUE PROPOSITION ANALYSIS
8.1. Overview and Methodology
8.2. Outreach-related Value
8.3. Developer Value
8.4. Product-related Value
8.5. Value to Patients
8.6. Concluding Remarks

9. COMPANY COMPETITIVENESS ANALYSIS
9.1. Overview and Methodology
9.2. Company Competitiveness Analysis
9.3. Concluding Remarks

Section II Analysis of Investments
10. FUNDING AND INVESTMENT ANALYS
IS
10.1. Overview
10.2. Analysis by Type of Funding
10.3. Analysis by Geography and Most Active Companies
10.4. Analysis of Trends Associated with Individual Funding Categories
10.5. Funding and Investments Summary

Section III Financial Analysis and Assessment of Business Risks
11. FINANCIAL ANALYSIS OF PUBLIC VENTURES

11.1. Fundamental Financial Analysis Overview
11.2. Financial Ratios (Interpretation Guide)
11.3. Case Study 1
11.4. Technical Financial Analysis Overview
11.5. Technical Indicators (Interpretation Guide)
11.6. Case Study 2

12. COMPANY PROFILES OF PUBLIC VENTURES
12.1 Akili Interactive
12.1.1. Key Highlights
12.1.1.1. Company Details
12.1.1.1. Company Overview
12.1.1.3. Insights from Balance Sheet
12.1.1.4. Management Team
12.1.1.5. Recent Developments

12.1.2. Key Financial Details
12.1.2.1. Company Investments
12.1.2.2. Company Fundamentals
12.1.2.3. Company Technicals

12.2. Better Therapeutics
12.2.1. Key Highlights
12.2.1.1. Company Details
12.2.1.1. Company Overview
12.2.1.3. Insights from Balance Sheet
12.2.1.4. Management Team
12.2.1.5. Recent Developments

12.2.2 Key Financial Details
12.2.2.1. Company Investments
12.2.2.2. Company Fundamentals
12.2.2.3. Company Technicals

12.3. Brain+
12.3.1. Key Highlights
12.3.1.1. Company Details
12.3.1.1. Company Overview
12.3.1.3. Insights from Balance Sheet
12.3.1.4. Management Team
12.3.1.5. Recent Developments

12.3.2. Key Financial Details
12.3.2.1. Company Investments
12.3.2.2. Company Fundamentals
12.3.2.3. Company Technicals

12.4. Dario Health
12.4.1. Key Highlights
12.4.1.1. Company Details
12.4.1.1. Company Overview
12.4.1.3. Insights from Balance Sheet
12.4.1.4. Management Team
12.4.1.5. Recent Developments

12.4.2 Key Financial Details
12.4.2.1. Company Investments
12.4.2.2. Company Fundamentals
12.4.2.3. Company Technicals

12.5. Ehave
12.5.1. Key Highlights
12.5.1.1. Company Details
12.5.1.1. Company Overview
12.5.1.3. Insights from Balance Sheet
12.5.1.4. Management Team
12.5.1.5. Recent Developments

12.5.2. Key Financial Details
12.5.2.1. Company Investments
12.5.2.2. Company Fundamentals
12.5.2.3. Company Technicals

12.6. Mindcure
12.6.1. Key Highlights
12.6.1.1. Company Details
12.6.1.1. Company Overview
12.6.1.3. Insights from Balance Sheet
12.6.1.4. Management Team
12.6.1.5. Recent Developments

12.6.2. Key Financial Details
12.6.2.1. Company Investments
12.6.2.2. Company Fundamentals
12.6.2.3. Company Technicals

12.7. Newtopia
12.7.1. Key Highlights
12.7.1.1. Company Details
12.7.1.1. Company Overview
12.7.1.3. Insights from Balance Sheet
12.7.1.4. Management Team
12.7.1.5. Recent Developments

12.7.2. Key Financial Details
12.7.2.1. Company Investments
12.7.2.2. Company Fundamentals
12.7.2.3. Company Technicals

12.8. Pear Therapeutics
12.8.1. Key Highlights
12.8.1.1. Company Details
12.8.1.1. Company Overview
12.8.1.3. Insights from Balance Sheet
12.8.1.4. Management Team
12.8.1.5. Recent Developments

12.8.2. Key Financial Details
12.8.2.1. Company Investments
12.8.2.2. Company Fundamentals
12.8.2.3. Company Technicals

12.9. Sharecare
12.9.1. Key Highlights
12.9.1.1. Company Details
12.9.1.1. Company Overview
12.9.1.3. Insights from Balance Sheet
12.9.1.4. Management Team
12.9.1.5. Recent Developments

12.9.2 Key Financial Details
12.9.2.1. Company Investments
12.9.2.2. Company Fundamentals
12.9.2.3. Company Technicals

13. BUSINESS RISK ANALYSIS
13.1. Overview and Methodology
13.2. Operations-related Risks
13.3. Business-related Risks
13.4. Financial / Asset-related Risks
13.5. Product / Technology Risks
13.6. Other Risks
13.7. Business Risk Summary

Section IV Market Forecast and Opportunity Analysis
14. MARKET FORECAST

14.1. Overview and Methodology
14.2. Global Digital Therapeutics Market, 2023-2035
14.3. Distribution Across Key Market Segments
14.3.1. Digital Therapeutics Market: Distribution by Type of Solution, 2023 and 2035
14.3.1.1. Digital Therapeutics Market for Standalone Software Application, 2023-2035
14.3.1.2. Digital Therapeutics Market for Combination Offerings (Software Application + Device), 2023-2035
14.3.1.3. Digital Therapeutics Market for Combination Offerings (Software Application + AI Support), 2023-2035
14.3.1.4. Digital Therapeutics Market for Combination Offerings (Software Application + Personal Coach), 2023-2035
14.3.1.5. Digital Therapeutics Market for Combination Offerings (Software Application + Device + AI Support), 2023-2035
14.3.1.6. Digital Therapeutics Market for Combination Offerings (Software Application + Device + Personal Coach), 2023-2035
14.3.1.7. Digital Therapeutics Market for Other Types of Solutions, 2023-2035
14.3.2. Digital Therapeutics Market: Distribution by Type of Therapy, 2023 and 2035
14.3.2.1. Digital Therapeutics Market for Curative Therapy, 2023-2035
14.3.2.2. Digital Therapeutics Market for Preventive Therapy, 2023-2035

14.3.3. Digital Therapeutics Market: Distribution by Therapeutic Area, 2023 and 2035
14.3.3.1. Digital Therapeutics Market for Cardiovascular Disorders, 2023-2035
14.3.3.2. Digital Therapeutics Market for Chronic Pain, 2023-2035
14.3.3.3 Digital Therapeutics Market for Mental Health Problems, 2023-2035
14.3.3.4 Digital Therapeutics Market for Metabolic Disorders, 2023-2035
14.3.3.5 Digital Therapeutics Market for Neurological Disorders, 2023-2035
14.3.3.6 Digital Therapeutics Market for Respiratory Disorders, 2023-2035
14.3.3.7 Digital Therapeutics Market for Sleep Disorders, 2023-2035
14.3.3.8 Digital Therapeutics Market for Substance Use Disorders, 2023-2035
14.3.3.9 Digital Therapeutics Market for Other Disorders, 2023-2035

14.3.4. Digital Therapeutics Market: Distribution by Geographical Regions, 2023 and 2035
14.3.4.1. Digital Therapeutics Market in North America, 2023-2035
14.3.4.2. Digital Therapeutics Market in Europe, 2023-2035
14.3.4.3. Digital Therapeutics Market in Asia-Pacific and Rest of the World, 2023-2035

Section V Analysis of Returns on Investment and Key Acquisition Targets 
15 ANALYSIS OF RETURNS ON INVESTMENT
15.1. Overview and Methodology
15.2. Case Studies
15.3. Concluding Remarks

16. KEY ACQUISITION TARGETS
16.1. Overview
16.2. List of Key Acquisition Targets
16.3. Concluding Remarks

17. CONCLUSION

18. APPENDICES

List Of Figures

Figure 5.1. Digital Therapeutics: Key Definitions and Background
Figure 5.2. Digital Therapeutics: Key Historical Milestones
Figure 5.3. Digital Therapeutics: Types of Solutions and Key Industry Players
Figure 5.4. Digital Therapeutics: Key Strategic Initiatives
Figure 5.5 Digital Therapeutics: Key Marketed Products and Challenges
Figure 6.1. Innovator Landscape: Distribution by Year of Establishment
Figure 6.2. Innovator Landscape: Distribution by Type of Venture
Figure 6.3. Innovator Landscape: Distribution by Company Size
Figure 6.4. Innovator Landscape: Distribution by Geography
Figure 7.1. Product Landscape: Distribution of Innovators by Number of Products
Figure 7.2. Product Landscape: Distribution by Type of Therapy
Figure 7.3. Product Landscape: Distribution of Products by Status of Development
Figure 7.4. Product Landscape: Distribution of Products by Type of Solution
Figure 7.5. Product Landscape: Distribution of Innovators by Therapeutic Area
Figure 8.1. Companies Offering Outreach-Related Value: Analysis of Companies Offering Very High Value
Figure 8.2. Companies Offering Developer Value: Analysis of Companies Offering Very High Value (2007-2013)
Figure 8.2. Companies Offering Developer Value: Analysis of Companies Offering Very High Value (2014-2018)
Figure 8.3. Companies Offering Product-related Value: Analysis of Companies Offering Very High Value
Figure 8.4. Companies Offering Value to Patients: Analysis of Companies Offering Very High Value
Figure 9.1. Competitiveness Analysis: Large Companies based in North America (Peer Group I)
Figure 9.2. Competitiveness Analysis: Mid-sized Companies based in North America (Peer Group II)
Figure 9.3. Competitiveness Analysis: Small Companies based in North America (Peer Group III)
Figure 9.4. Competitiveness Analysis: Very Small Companies based in North America (Peer Group IV)
Figure 9.5. Competitiveness Analysis: Large and Mid-sized Companies based in Europe (Peer Group V)
Figure 9.6. Competitiveness Analysis: Small Companies based in Europe (Peer Group VI)
Figure 9.7. Competitiveness Analysis: Very Small Companies based in Europe (Peer Group VII)
Figure 9.8. Competitiveness Analysis: Mid-sized Companies based in Asia-Pacific and Rest of the World (Peer Group VIII)
Figure 9.9. Competitiveness Analysis: Small and Very Small Companies based in Asia-Pacific and Rest of the World (Peer Group IX)
Figure 9.10. Concluding Remarks: Strategies for Growing and Sustaining Business Competency
Figure 10.1. Funding and Investment Analysis: Cumulative Year-wise Distribution of Funding Instances and Amount Invested (2011-2022)
Figure 10.2. Funding and Investment Analysis: Distribution of Instances by Type of Funding
Figure 10.3. Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding
Figure 10.4. Funding and Investment Analysis: Geographical Distribution
Figure 10.5. Funding and Investment Analysis: Most Active Players (Number of Instances)
Figure 10.6. Funding and Investment Analysis: Most Active Players (Capital Amount Raised)
Figure 10.7. Awards / Grants: Cumulative Instances & Amount Invested (USD Million)
Figure 10.8. Awards / Grants: Global Distribution of Amount Invested
Figure 10.9. Awards / Grants: Most Active Investors
Figure 10.10. Seed Funding: Cumulative Instances & Amount Invested (USD Million)
Figure 10.11. Seed Funding: Global Distribution of Amount Invested
Figure 10.12. Seed Funding: Most Active Investors
Figure 10.13. Private Placements: Cumulative Instances & Amount Invested (USD Million)
Figure 10.14. Private Placements: Global Distribution of Amount Invested
Figure 10.15. Private Placements: Most Active Investors
Figure 10.16. Debt Financing: Cumulative Instances & Amount Invested (USD Million)
Figure 10.17. Debt Financing: Global Distribution of Amount Invested
Figure 10.18. Debt Financing: Most Active Investors
Figure 10.19. Venture (Series A): Cumulative Instances & Amount Invested (USD Million)
Figure 10.20. Venture (Series A): Global Distribution of Amount Invested
Figure 10.21. Venture (Series A): Most Active Investors
Figure 10.22. Venture (Series B): Cumulative Instances & Amount Invested (USD Million)
Figure 10.23. Venture (Series B): Global Distribution of Amount Invested
Figure 10.24. Venture (Series B): Most Active Investors
Figure 10.25. Venture (Series C): Cumulative Instances & Amount Invested (USD Million)
Figure 10.26. Venture (Series C): Global Distribution of Amount Invested
Figure 10.27. Venture (Series C): Most Active Investors
Figure 10.28. Venture (Series D): Cumulative Instances & Amount Invested (USD Million)
Figure 10.29. Venture (Series D): Global Distribution of Amount Invested
Figure 10.30. Venture (Series D): Most Active Investors
Figure 10.31. Venture (Series E, F, G and Unknown): Cumulative Instances & Amount Invested (USD Million)
Figure 10.32. Venture (Series E, F, G and Unknown): Global Distribution of Amount Invested
Figure 10.33. Venture (Series E, F, G and Unknown): Most Active Investors
Figure 10.34. Public Offering: Cumulative Instances & Amount Invested (USD Million)
Figure 10.35. Public Offering: Global Distribution of Amount Invested
Figure 10.36. Public Offering: Most Active Investors
Figure 10.36. Capital Investments in Digital Therapeutics Company: Summary of Investments, 2011-2022
Figure 12.1. Akili Interactive: Company Fundamentals
Figure 12.2. Akili Interactive: Trend of Stock Prices Since Initial Public Offering
Figure 12.3. Better Therapeutics: Company Fundamentals
Figure 12.4. Better Therapeutics: Trend of Stock Prices Since Initial Public Offering
Figure 12.5. Brain+: Company Fundamentals
Figure 12.6. Brain+: Trend of Stock Prices Since Initial Public Offering
Figure 12.7. Dario Health: Company Fundamentals
Figure 12.8. Dario Health: Trend of Stock Prices Since Initial Public Offering
Figure 12.9. Ehave: Company Fundamentals
Figure 12.10. Ehave: Trend of Stock Prices Since Initial Public Offering
Figure 12.11. Mindcure: Company Fundamentals
Figure 12.12. Mindcure: Trend of Stock Prices Since Initial Public Offering
Figure 12.13. Newtopia: Company Fundamentals
Figure 12.14. Newtopia: Trend of Stock Prices Since Initial Public Offering
Figure 12.15. Pear Therapeutics: Company Fundamentals
Figure 12.16. Pear Therapeutics: Trend of Stock Prices Since Initial Public Offering
Figure 12.15. Sharecare: Company Fundamentals
Figure 12.16. Sharecare: Trend of Stock Prices Since Initial Public Offering
Figure 13.1. Business Risk Analysis: Operations-related Risks
Figure 13.2. Business Risk Analysis: Business-related Risks
Figure 13.3. Business Risk Analysis: Financial / Asset-related Risks
Figure 13.4. Business Risk Analysis: Product / Technology Risks
Figure 13.5. Business Risk Analysis: Other Risks
Figure 13.6. Summary of Business Risk Analysis
Figure 14.1. Digital Therapeutics Market: Forecast, 2023-2035 (USD Million)
Figure 14.2. Digital Therapeutics Market: Distribution by Type of Solution, 2023 and 2035
Figure 14.3 Digital Therapeutics Market for Standalone Software Applications, 2023-2035 (USD Million)
Figure 14.4. Digital Therapeutics Market for Combination Offerings (Software Application + Device + Personal Coach), 2023-2035 (USD Million)
Figure 14.5 Digital Therapeutics Market for Combination Offerings (Software Application + Device + AI Support), 2023-2035 (USD Million)
Figure 14.6 Digital Therapeutics Market for Combination Offerings (Software Application + Device), 2023-2035 (USD Million)
Figure 14.7 Digital Therapeutics Market for Combination Offerings (Software Application + AI Support), 2023-2035 (USD Million)
Figure 14.8 Digital Therapeutics Market for Combination Offerings (Software Application + Personal Coach), 2023-2035 (USD Million)
Figure 14.9 Digital Therapeutics Market for Other Types of Solutions, 2023-2035 (USD Million)
Figure 14.10. Digital Therapeutics Market: Distribution by Type of Therapy, 2023 and 2035
Figure 14.11 Digital Therapeutics Market for Curative Therapy, 2023-2035 (USD Million)
Figure 14.12 Digital Therapeutics Market for Preventive Therapy, 2023-2035 (USD Million)
Figure 14.13 Digital Therapeutics Market: Distribution by Therapeutic Area, 2023 and 2035
Figure 14.14 Digital Therapeutics Market for Cardiovascular Disorders, 2023-2035 (USD Million)
Figure 14.15 Digital Therapeutics Market for Chronic Pain, 2023-2035 (USD Million)
Figure 14.16 Digital Therapeutics Market for Mental Health Problems, 2023-2035 (USD Million)
Figure 14.17 Digital Therapeutics Market for Metabolic Disorders, 2023-2035 (USD Million)
Figure 14.18 Digital Therapeutics Market for Neurological Disorders, 2023-2035 (USD Million)
Figure 14.19 Digital Therapeutics Market for Respiratory Disorders, 2023-2035 (USD Million)
Figure 14.20 Digital Therapeutics Market for Sleep Disorders, 2023-2035 (USD Million)
Figure 14.21 Digital Therapeutics Market for Substance Use Disorders, 2023-2035 (USD Million)
Figure 14.22 Digital Therapeutics Market for Other Disorders, 2023-2035 (USD Million)
Figure 14.23 Digital Therapeutics Market: Distribution by Key Geographical Regions, 2023 and 2035
Figure 14.24 Digital Therapeutics Market in North America, 2023-2035 (USD Million)
Figure 14.25 Digital Therapeutics Market in Europe, 2023-2035 (USD Million)
Figure 14.26 Digital Therapeutics Market in Asia-Pacific and Rest of the World, 2023-2035 (USD Million)
Figure 16.1. Key Acquisition Targets: Comparison of Scores with Overall Dataset
Figure 16.2. Key Acquisition Targets: Comparison based on Qualifying Parameters (1/4)
Figure 16.3. Key Acquisition Targets: Comparison based on Qualifying Parameters (2/4)
Figure 16.4. Key Acquisition Targets: Comparison based on Qualifying Parameters (3/4)
Figure 16.5. Key Acquisition Targets: Comparison based on Qualifying Parameters (4/4)
Figure 17.1. Concluding Landscape: North America
Figure 17.2. Concluding Landscape: Europe
Figure 17.3. Concluding Landscape: Asia-Pacific

List Of Tables

Table 6.1. Key Innovators in the Digital Therapeutics Market
Table 7.1. Products Offered by Innovators in the Digital Therapeutics Market
Table 7.2. Company Health Indexing (1/15)
Table 7.3. Company Health Indexing (2/15)
Table 7.4. Company Health Indexing (3/15)
Table 7.5. Company Health Indexing (4/15)
Table 7.6. Company Health Indexing (5/15)
Table 7.7. Company Health Indexing (6/15)
Table 7.8. Company Health Indexing (7/15)
Table 7.9. Company Health Indexing (8/15)
Table 7.10. Company Health Indexing (9/15)
Table 7.11. Company Health Indexing (10/15)
Table 7.12. Company Health Indexing (11/15)
Table 7.13. Company Health Indexing (12/15)
Table 7.14. Company Health Indexing (13/15)
Table 7.15. Company Health Indexing (14/15)
Table 7.16. Company Health Indexing (15/15)

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. 11.2 Capital
  2. 2breathe Technologies
  3. 2Morrow
  4. 3L
  5. 3M Ventures
  6. 3VC
  7. 4point0 Health Ventures
  8. 500 Startups
  9. 5AM Ventures
  10. 7wire Ventures
  11. 9 Unicorns
  12. A-Round Capital
  13. A195 Capital
  14. Ababax Health
  15. Accel
  16. Accelmed
  17. Act Venture Capital
  18. Advance Venture Partners
  19. Advantage Capital
  20. AET Fund
  21. Aflac
  22. AI Fund
  23. AIB Seed Capital Fund
  24. aidhere
  25. Autisms Impact Fund
  26. Akili Interactive
  27. Akilia Partners
  28. Albion Capital
  29. AlbionVC
  30. Alex therapeutics
  31. Alfvén & Didrikson
  32. Alkeon Capital Management
  33. Allen & Company
  34. Alliance Global Partners (A.G.P.)
  35. Ally Bridge Group
  36. Alsace Business Angels
  37. Alumni Ventures
  38. Amalgam
  39. Amara Therapeutics
  40. Amazon Smbhav Venture Fund
  41. AME Cloud Partners
  42. AME Cloud Ventures
  43. Amelia
  44. American Investment Holdings
  45. Amgen Ventures
  46. Amiko Digital Health
  47. aMoon
  48. Ampersand Health
  49. Amplify Capital
  50. Ancora
  51. Andreessen Horowitz
  52. Anorak Ventures
  53. Anthemis
  54. Aphelion Capital
  55. AppliedVR
  56. Aptar Pharma
  57. Arboretum Ventures
  58. Ardea Capital Partners
  59. ArrowMark Partners
  60. Asabys Partners
  61. Asahi Kasei
  62. Aspect Ventures
  63. Atlantic Labs
  64. Atomico
  65. ATX Therapeutics
  66. Aviva Ventures
  67. AXA Venture Partners (AVP)
  68. Axil Capital
  69. B Capital
  70. Baillie Gifford
  71. Balderton Capital
  72. Baseline Ventures
  73. Bayer
  74. Beats Medical
  75. BeCareLink
  76. BEENEXT
  77. BehaVr
  78. Beneufit
  79. Bertelsmann Investments
  80. Bessemer Venture Partners
  81. Better Therapeutics
  82. Beyond Next Ventures
  83. Big Health
  84. Bimark
  85. Biofourmis
  86. BioTrak Therapeutics
  87. BIXINK
  88. Blackbird Ventures
  89. BlackRock
  90. Blackstone
  91. BlissDTx
  92. Bloom Burton
  93. Blue Cross Blue Shield of Massachusetts
  94. Blue Cross Blue Shield Venture Partners
  95. Blue Mesa Health
  96. Blue Note therapeutics
  97. Blue Venture Funds
  98. Blue Water Life Science Fund
  99. Blueprint Health
  100. BlueRun Ventures
  101. Boehringer Ingelheim
  102. Boehringer Ingelheim Venture Fund
  103. Bold Capital Partners
  104. Bold Health
  105. Bonit Capital
  106. Bose Ventures
  107. Bpifrance
  108. Brain Power
  109. Brain+
  110. Brandenburg Capital
  111. Bridge Bank
  112. Bridge Builders Collaborative
  113. Brooklands Capital Strategies
  114. Business Finland
  115. Cabin VC
  116. Caffeinated Capital
  117. Caixa Capital Risc
  118. Canaan Partners
  119. Canepa Advanced Healthcare Fund
  120. Canaan
  121. Canvas
  122. Canvas Ventures
  123. Medvest
  124. Cara.Care
  125. CardioRenal
  126. CAREvolution
  127. Carlyle
  128. Carrot Health
  129. Castle Peak (Acquired by CLP Holdings)
  130. Cedars-Sinai
  131. Centene
  132. CG Ventures
  133. CheckUp & Choices
  134. Chibagin Capital
  135. Cigna
  136. Cigna Ventures
  137. Cipla
  138. City Light Capital
  139. Civilization Ventures
  140. Click Therapeutics
  141. CLSA
  142. Coatue Management
  143. Cognoa
  144. COLOPL VR Fund
  145. Community Health Network of Connecticut
  146. Company K Partners
  147. Concord Health Partners
  148. Constant Therapy Health
  149. Correlation Ventures
  150. Cowen Private Investments
  151. CRCM Ventures
  152. Creandum
  153. Creas
  154. Creative Destruction Lab
  155. CrimsoNox Capital
  156. Crista Galli Ventures
  157. CureApp
  158. Curio
  159. Currae Healthtech
  160. CVS Health
  161. Cyberdine
  162. Dai-ichi Life
  163. DarioHealth
  164. dayzz
  165. Deerfield
  166. Deerfield Management Company
  167. Dendera Ventures
  168. Department of Defense
  169. Dexium Technologies
  170. DFJ
  171. DG Ventures
  172. Digbi Health
  173. Digithera
  174. DigiTx Partners
  175. DN Capital
  176. Dnurse Technology
  177. Doha Tech Angels
  178. Dopavision
  179. Double Peak Group
  180. Dreamit Ventures
  181. dreem
  182. Driehaus Capital Management
  183. Droobi Health
  184. dThx – Digital Therapeutics
  185. Duopharma Biotech
  186. e&
  187. Echo Health Ventures
  188. Eco-Fusion
  189. EDBI
  190. Eden Strategy Institute
  191. Ehave
  192. Eight Roads Ventures
  193. Eisai
  194. EIT Health
  195. Eleven Two Capital
  196. Ellerca Health
  197. Embr Labs
  198. Emperra
  199. Endeavor Catalyst
  200. ENDRA Life Sciences
  201. Enterprise Ireland
  202. Entrée Capital
  203. Equity4Good
  204. Esther Dyson
  205. Eurazeo
  206. European Union
  207. Eurostars
  208. Evidity Health Capital
  209. Exosystems
  210. Expon Capital
  211. Exponential Ventures
  212. Farallon Capital Management
  213. Fearless Ventures
  214. Feel Therapeutics
  215. Felicis Ventures
  216. Fenbushi Capital
  217. FFF Bayern
  218. Fidelity Management and Research Company
  219. Fifty Years
  220. FinTLV Ventures
  221. Fireside Ventures
  222. FirstMark Capital
  223. Fitterfly
  224. Floreo
  225. Flying Health
  226. FMZ Ventures
  227. Forth Management
  228. Founders Fund
  229. Foundry
  230. F-Prime Capital
  231. Franklin Templeton
  232. Freespira
  233. Freestyle Capital
  234. Frontier Venture Capital
  235. Fruit Street
  236. Frumtak Ventures
  237. Fundalogy
  238. Future Perfect Ventures
  239. Gaingels
  240. Galen Partners
  241. gBETA Medtech
  242. GC VR Tracker Fund
  243. Gelt Venture Capital
  244. General Atlantic
  245. General Catalyst
  246. Genesis Ventures
  247. Georgian Partners
  248. Giant Leap
  249. Gilde Healthcare
  250. Ginger
  251. GingerBread Capital
  252. Global Brain
  253. Global Founders Capital
  254. GlobalYeast
  255. Glooko
  256. Golden Seeds
  257. Green Shield Canada
  258. GrowX Venture Management
  259. GSR Ventures
  260. GuideWell Mutual Holding Corporation
  261. gumi Cryptos Capital
  262. H.I.G. BioHealth Partners
  263. Hadean Ventures
  264. Happify Health
  265. Healios
  266. Health Catalyst Capital
  267. HealthCap
  268. Heartcore Capital
  269. Hedia
  270. Hello Heart
  271. HelloBetter
  272. Hercules Capital
  273. Heritas Capital
  274. Heuristic Capital Partners
  275. Hevella Capital
  276. H ighmark Interactive
  277. High-Tech Gründerfonds
  278. Hikma Ventures
  279. Hinduja Group
  280. Hinge Health
  281. Holmusk
  282. Hyde Park Angels
  283. I Mercury Capital
  284. IBB Beteiligungsgesellschaft
  285. Idinvest
  286. iFeel Labs
  287. impute
  288. Incos Invest
  289. Industry Ventures
  290. i-nest capital
  291. INFOR Financial
  292. InHealth Ventures
  293. inMotion VR
  294. Innovate UK
  295. Innovation Works
  296. Insight Partners
  297. Insulet
  298. InsurTech.vc
  299. Integra Partners
  300. Intel Capital
  301. Intermountain Healthcare
  302. International Capital & Management Company (ICMC)
  303. Invest Detroit
  304. Investec
  305. Investitionsbank des Landes Brandenburg (ILB)
  306. ION Crossover Partners
  307. iSeed Ventures
  308. IT-Farm
  309. ITOCHU
  310. ITOCHU Technology Ventures (ITV)
  311. IVP
  312. Iwagin Business Creation Capital
  313. Iwagin Jigyo Souzou Capital
  314. J.P. Morgan
  315. JamJar Investments
  316. Janssen Research & Development
  317. Japan Impact Investment II
  318. JAZZ Venture Partners
  319. Jeff Weiner
  320. Jianke
  321. JOGO Health
  322. Johnson & Johnson Innovation
  323. Joint Academy
  324. Jolly Good
  325. Joy Ventures
  326. Joyable
  327. Joyance Partners
  328. K2 HealthVentures
  329. K2 Investment Partners
  330. Kaia Health
  331. Kaiser Permanente Ventures
  332. Kakao Ventures
  333. Kapor Capital
  334. Karista
  335. Karuna Labs
  336. Keio Innovation Initiative
  337. Kelvi
  338. Kenetic Advisors
  339. Kentucky Science and Technology Corporation (KSTC)
  340. Khosla Ventures
  341. Kicker Ventures
  342. Kiio
  343. Kima Ventures
  344. King River Capital
  345. Kinnevik
  346. KLAVA Innovation
  347. Kleiner Perkins
  348. Kleiner Perkins Caufield & Byers
  349. Koa Health
  350. KORE Digital Health Therapeutics
  351. Korea Investment Partners
  352. Korea Technology Finance
  353. Kortex Ventures
  354. Koshidaka
  355. Kranus Health
  356. KTB Network
  357. Kurbo Health
  358. Kwit
  359. Ladera Venture Partners
  360. Laguna Investment
  361. Laia Contigo
  362. Laidir Foundation
  363. Lark Health
  364. LaunchPad Venture Group
  365. Lead Edge Capital
  366. LEAP Axlr8r
  367. Leaps by Bayer
  368. Learn Capital
  369. Leksell Social Ventures (LSV)
  370. Lief Therapeutics
  371. LifeForce Capital
  372. Lifeline Ventures
  373. Lightspeed Venture Partners
  374. Limbix
  375. Limedix
  376. LionBirds
  377. Liquid 2 Ventures
  378. Livongo Health
  379. LongHash Ventures
  380. LRVHealth
  381. LUCID
  382. Lund University
  383. Lux Capital
  384. M Ventures
  385. M3 Ventures
  386. Magellan Health
  387. Magnetic Ventures
  388. Mahana Therapeutics
  389. MAIF Avenir
  390. Maine Technology Institute (MTI)
  391. Mana Ventures
  392. Manipal Education and Medical Group
  393. Manufacturers Life Insurance (Manulife)
  394. Massachusetts Life Sciences Center
  395. MassChallenge
  396. MassMutual Ventures
  397. Maven Ventures
  398. Maverick Ventures
  399. Mawendo
  400. Mayo Clinic
  401. McKesson Ventures
  402. MedRhythms
  403. Medtronic
  404. Melon Health
  405. mementor (Acquired by ResMed)
  406. Memorial Sloan Kettering Cancer Center
  407. MemorialCare Innovation Fund (MCIF)
  408. Merck Global Health Innovation Fund
  409. Merck Ventures
  410. Meru Health
  411. metaMe
  412. Metrodora Ventures
  413. Microsoft Ventures
  414. MiLA Capital
  415. MINDCURE
  416. Mindable Health
  417. MindBeacon Group
  418. MindMaze
  419. Mindset Health
  420. Mirae Asset Capital
  421. Mitsubishi UFJ Capital
  422. Mizuho Capital
  423. Mobio Technologies
  424. Molbio diagnostics
  425. Monashee Investment Management
  426. Montage Ventures
  427. Moonwhale Ventures
  428. Morningside Group
  429. Morningside Ventures
  430. moveUP
  431. MTIP
  432. Mundi Ventures
  433. Mundipharma
  434. My mhealth
  435. mynoise
  436. Naluri
  437. Nantahala Capital Management
  438. National Institute of Health
  439. National Institute of Mental Health
  440. National Institute on Aging
  441. National Science Foundation
  442. NCL Investment Management
  443. Neuberger Berman
  444. Neuroglee Therapeutics
  445. Neurotrack
  446. New Enterprise Associates
  447. New Leaf Venture Partners
  448. Newsenselab
  449. Newtopia
  450. NEXT Canada
  451. NextGen Venture Partners
  452. NGP Capital
  453. NightWare
  454. Nimble Ventures
  455. Nimbus Synergies
  456. Nina Capital
  457. Noaber
  458. Nokia Growth Partners
  459. Noom
  460. Nordic Brain Tech
  461. Nori Health
  462. Northwell Holdings
  463. Norwest Venture Partners
  464. Novartis
  465. Novartis Pharmaceuticals
  466. Novator Partners
  467. Novego
  468. Novo Holdings
  469. Novo Nordisk
  470. Nunaps
  471. Oak HC/FT
  472. Obvious Ventures
  473. Ocean Azul Partners
  474. Octopus Ventures
  475. Olive Tree Capital
  476. Omada Health
  477. Omega Capital
  478. Omidyar Technology Ventures
  479. OMRON Global
  480. One Drop
  481. ONE WORLD
  482. Openspace Ventures (formerly NSI Ventures)
  483. Optum Ventures
  484. OrbiMed
  485. OSF Ventures
  486. OurCrowd
  487. Oviva
  488. Ovulai
  489. Owl Ventures
  490. Ozential
  491. PaceZero Capital Partners
  492. Pacific Health Ventures
  493. Paretch
  494. Pathology Asia
  495. PayPal
  496. PBJ Capital
  497. Pear Therapeutics
  498. Pegasus Tech Ventures
  499. Peppermint VenturePartners
  500. Perceptive Advisors
  501. PFM Health Sciences
  502. Phenomenelle Angels
  503. Philips
  504. Phoenix Insurance
  505. Picus Capital
  506. PilotHouse
  507. Playground Global
  508. Plug and Play
  509. Polaris Partners
  510. Pond Capital
  511. Portland Seed Fund
  512. PrehApp
  513. PreSeedVentures
  514. Presence Capital
  515. Prodeko Ventures
  516. Propeller Health
  517. Prototron
  518. Providence Ventures
  519. Pura Vida Investments
  520. PureTech Health
  521. Quad
  522. Quadrille Capital
  523. Qure Ventures
  524. Rally Health
  525. Reaktor Ventures
  526. RediCare
  527. Redmile Group
  528. Rehappy
  529. Resolute Ventures
  530. Restore Health
  531. Rethink Impact
  532. Revelation Partners
  533. Revon Systems
  534. RHL Ventures
  535. RhythmiaBreath
  536. Ridgetop Health
  537. Roblox
  538. RRE Ventures
  539. Saama Technologies
  540. Safar Partners
  541. Safeguard Scientifics
  542. SAIF Partners
  543. Saisei Ventures
  544. Saison Ventures
  545. Salumedia
  546. Samsung Ventures
  547. Sanofi Ventures
  548. Sanofi-Genzyme BioVentures
  549. Sapien Ventures
  550. Sapphire Ventures
  551. Sarissa Capital Management
  552. Sarjan Health
  553. SBI Investment
  554. SBRI Healthcare
  555. Scale Capital
  556. Schoolhouse Partners
  557. ScientificMed
  558. SciFi VC
  559. Sectoral Asset Management
  560. SeedtoB Capital
  561. SelfBack
  562. Sequoia
  563. Sequoia Capital
  564. Seraph
  565. Serena Ventures
  566. SGInnovate
  567. Shanda Group
  568. Sharecare
  569. Shinsei Corporate Investment
  570. Shionogi
  571. Shoko Chukin Bank
  572. Sidekick Health
  573. Signia Venture Partners
  574. Silicon Valley Bank
  575. Silver Lake
  576. SilverCloud (Acquired by Anwell)
  577. Simplyhealth
  578. Sivan Innovation
  579. Skip Battle
  580. SMBC Venture Capital
  581. Social Capital
  582. Social Capital Suvretta Holdings
  583. Social Starts
  584. Sofina
  585. Soft Tech
  586. SoftBank Vision
  587. SoftBank Vision Fund
  588. Sompo Holdings
  589. Sonormed
  590. Sony Innovation Fund
  591. Sophia Bendz
  592. SOS Ventures
  593. Sozo Ventures
  594. SparkLabs
  595. Sparrow Ventures
  596. SpesNet
  597. Spice Capital
  598. SR One Capital Management
  599. Stanford Technology Ventures Program (STVP)
  600. Stanley Park Ventures
  601. Startmate
  602. Startupbootcamp Digital Health Berlin
  603. StartX
  604. Stateline Angels
  605. SternAegis Ventures
  606. STIFEL
  607. Storm Ventures
  608. Stress Point Health
  609. Sumitomo Mitsui Trust Holdings
  610. Summer VC
  611. Summit Partners
  612. SUSMED
  613. Sway Ventures
  614. Sweet Capital
  615. sweetch
  616. Swing Therapeutics
  617. Sympatient
  618. Symphony
  619. Tal Ventures
  620. Techstars
  621. Teladoc Health
  622. TELUS Ventures
  623. Temasek
  624. The Valley Fund
  625. The Venture Reality Fund
  626. The Vertical Group
  627. Think.Health
  628. Tiger Global
  629. Tokyo Century
  630. TomorrowVentures
  631. Toyoshima & Co
  632. Trend Forward Capital
  633. Trinity Capital
  634. Triumf Health
  635. Trustbridge
  636. TT Capital Partners
  637. Turnaround Health
  638. U.S. Venture Partners
  639. Ulster Bank Diageo Venture Fund (Investec Ventures)
  640. Unconventional Ventures
  641. UnityPoint Health Ventures
  642. UpLift Health
  643. Velmio
  644. Venrock
  645. Venture Catalysts
  646. Verve Capital Partners
  647. Verve Ventures
  648. Vida Health
  649. Vigo
  650. Virta Health
  651. Virtue Health
  652. Vitadio
  653. Vivid Vision
  654. ViViRA
  655. Wakestream Ventures
  656. Walking Ventures
  657. Wanxiang America Corporation
  658. Wayra
  659. WEA Trust
  660. Webb Investment Network
  661. Wellington Management Company
  662. Wellington Partners
  663. Wells Fargo Capital Finance
  664. Wellstreet
  665. Wellthy Therapeutics
  666. Werth Family Investment Associates
  667. Whale Rock Capital Management
  668. White Fund
  669. Wisconsin Investment Partners
  670. Wisdom
  671. Woebot Health
  672. Workday Ventures
  673. Workit Health
  674. WP Global Partners
  675. WRF Capital
  676. Y Combinator
  677. Zaffre Investments
  678. Zenworks
  679. ZINC

Source 1: https://www.digital-adoption.com/digital-adoption-healthcare-research/
Source 2: https://sdlcpartners.com/insights/what-is-digital-therapeutics/

PRICING DETAILS

USD 1,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com